Effects of the mouthpiece and chamber of Turbuhaler® on the aerosolization of API-only powder formulations

Zhu, Qixuan; Gou, Dazhao; Chan, Hak-Kim; Kourmatzis, Agisilaos; Yang, Runyu

doi:10.1016/j.ijpharm.2023.122871

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dispersion depended on the drag force on the particle from the airflow, the interaction force between particles, and the collisions between the particles and spiral channel when DPI particles were released from the Turbuhaler ® [ 54 ]. For the mechanical dry-coating process, although the rupture force of the agglomerated particles was reduced to improve dispersion, the mechanical strength was maintained at about 4 mN and failed to decrease with increasing MgSt concentration.…”

Section: Discussionmentioning

confidence: 99%

Improving Inhalation Performance with Particle Agglomeration via Combining Mechanical Dry Coating and Ultrasonic Vibration

Zhang,

Wang,

Shi

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Agglomerate formulations for dry powder inhalation (DPI) formed with fine particles are versatile means for the highly efficient delivery of budesonide. However, uncontrolled agglomeration induces high deposition in the upper airway, causing local side effects due to high mechanical strength, worse deagglomeration, and poor fine-particle delivery. In the present study, fine lactose was mechanically dry-coated prior to particle agglomeration, and the agglomerates were then spheroidized via ultrasonic vibration to improve their aerosol performance. The results showed that the agglomerate produced with the surface-enriched hydrophobic magnesium stearate and ultrasonic vibration demonstrated improved aerosolization properties, benefiting from their lower mechanical strength, less interactive cohesive force, and improved fine powder dispersion behavior. After dispersion utilizing a Turbuhaler® with a pharmaceutical cascade impactor test, a fine particle fraction (FPF) of 71.1 ± 1.3% and an artificial throat deposition of 19.3 ± 0.4% were achieved, suggesting the potential to improve the therapeutic outcomes of budesonide with less localized infections of the mouth and pharynx.

show abstract

Section: Discussionmentioning

confidence: 99%